Written Authority Required Drugs

Breast cancer - locally advanced HER2 positive breast cancer

The PBS subsidises trastuzumab for patients with human epidermal growth factor receptor 2 (HER2) positive locally advanced breast cancer.

Patient eligibility

Treatment with trastuzumab can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under the National Health Act 1953, Section 85 and Section 100—for the Efficient Funding of Chemotherapy, for a patient with HER2 positive locally advanced breast cancer.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits outlines the restrictions for prescribing trastuzumab.


From 1 July 2018, you can call the PBS Complex Drugs Programs enquiry line to make initial authority applications for early HER2 positive breast cancer.

Initial treatment

Make all initial applications for authority approval to prescribe trastuzumab for the treatment of HER2 positive locally advanced breast cancer in writing and:

All applications must include the completed:

The prescription must clearly state if the IV or SC route of administration is requested.

Continuing treatment

To make continuing applications for treatment with trastuzumab call the PBS Complex Drugs Programs enquiry line.

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

This information was printed Thursday 23 May 2019 from https://www.humanservices.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/breast-cancer-locally-advanced-her2-positive-breast-cancer It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.humanservices.gov.au/individuals/site-notices when using this material.

Page last updated: 22 February 2019